Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

November 20, 2022

Study Completion Date

November 20, 2022

Conditions
Retina DiseaseRetinopathy of PrematurityRanibizumab
Interventions
DRUG

Ranibizumab (0.25 mg/0.025 mL)

Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.

Trial Locations (1)

44511

Zagazig University, Faculty of medicine, Zagazig

All Listed Sponsors
collaborator

Cairo University

OTHER

lead

Zagazig University

OTHER_GOV